massively parallel sequencing
European Union to Review Illumina's Planned Grail Acquisition Under New Guidance
Illumina reaffirmed its commitment to the $8 billion deal and said it does not believe the European authorities have jurisdiction to review it.
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.
FTC Moves to Block Illumina's $8B Grail Acquisition
Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.
Twist Bioscience, Biotia Nab FDA EUA for Hybridization-Based NGS SARS-CoV-2 Assay
The hybridization-based test may provide better detection of emerging COVID-19 variants of concern, due to a higher tolerance for probe mismatches than in PCR.
Illumina, Geneseeq Technology to Collaborate on IVD Cancer Testing Kits in China
The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.